Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + Trametinib in Advanced Solid Tumors
NCT02703571Phase 1Terminated
- Sponsor
- Novartis
- Start
- Jun 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of ribociclib and trametinib in solid tumor, pancreatic cancer (PC) and colorectal cancer (CRC), sponsored by Novartis. Primary endpoints: Incidence of dose limiting toxicities at 21 days and Objective Response Rate up to 1 year. Started Jun 2016; status: terminated.
02
Drugs
ribociclibtrametinib
03
Conditions
solid tumorpancreatic cancer (PC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02703571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703571.